

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer ID1096

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u> Roche Products (pertuzumab)</p> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency • Cancer Black Care • Cancer Equality • Cancer52 • HAWC • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie’s Centres • Marie Curie Cancer Care • Muslim Council of Britain • Oesophageal Patients Association • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Surgeons of Great Britain and Ireland • British Association of Surgical Oncology • British Geriatric Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society of Gastroenterology • Cancer Research UK • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • All Wales Therapeutics and Toxicology Centre • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> • Accord Healthcare (capecitabine, cisplatin, fluorouracil) • Activis (capecitabine) • Allergan (fluorouracil) • Dr Reddy’s Laboratories (capecitabine) • Hospira UK (cisplatin, fluorouracil) • Medac UK (capecitabine, fluorouracil) • Morningside Healthcare (capecitabine) • Mylan (capecitabine) • Sandoz (cisplatin) • Roche Products (trastuzumab)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Health Forum • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Herefordshire CCG • NHS Waltham Forest CCG • Welsh Government 	<ul style="list-style-type: none"> • Teva UK (cisplatin) • Wockhardt UK (cisplatin) • Zentiva (capecitabine) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • CORE – The Digestive Disorders Foundation • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.